pharma · Dravet Syndrome · Dravet syndrome · STOK
Stoke Therapeutics
Stoke Therapeutics clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Bedford, USA
- Founded
- 2017
- Employees
- 205
- Programs
- 8
- Drugs
- 4
- Patents
- 14
Stoke Therapeutics projects
8 ClinicalTrials.gov programs sponsored by Stoke Therapeutics.
Stoke Therapeutics has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
STK-001, STK-001
Stoke Therapeutics
Dravet syndrome
1 trial -
zorevunersen
Stoke Therapeutics
Dravet Syndrome
1 trial -
Milrinone
Stoke Therapeutics
Valvular Stenosis
1 trial -
STK-001 - Single Ascending Doses
Stoke Therapeutics
Dravet Syndrome
1 trial -
zorevunersen (STK-001)
Stoke Therapeutics
Dravet Syndrome
1 trial -
STK-002
Stoke Therapeutics
Autosomal Dominant Optic Atrophy
1 trial -
Pethidine
Stoke Therapeutics
Pain Relief in Labour
1 trial -
Transanal irrigation with Peristeen Anal Irrigation
Stoke Therapeutics
Constipation
1 trial
Frequently asked questions
How many clinical projects does Stoke Therapeutics have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.